Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Filings indexed 50 across all filing types
Latest filing 2021-08-18 Regulatory Filings
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-08-18 English
Other securityholders documents - English.pdf
Regulatory Filings
2021-08-18 English
Other securityholders documents - English.pdf
Regulatory Filings
2021-08-18 English
Notice.pdf
Regulatory Filings
2021-08-17 English
Material change report - English.pdf
Regulatory Filings
2021-08-17 English
News release - English.pdf
Regulatory Filings
2021-08-17 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.